Xavier’s practice includes a variety of health care regulatory, fraud and abuse, and reimbursement issues in health care transactions and business arrangements. He represents clients that are involved in, or invest in, the health care and life sciences industries.
Xavier provides regulatory counsel to private equity firms and other investors in mergers and acquisitions involving a variety of targets, including health systems and other health care providers, pharmacies, health insurance plans, laboratories, health care technology companies, and risk adjustment vendors.
He routinely advises clients on a wide variety of federal and state health care regulatory issues, including fraud and abuse, licensure and scope of practice rules, telehealth, certificate of need applications, and genetic privacy. He has a particular focus on regulatory and compliance matters for health plans participating in Medicare Advantage, Medicare Part D, and Medicaid Managed Care programs.
On behalf of health care providers, Xavier handles licensure and regulatory filings, particularly in the context of transactions. He also routinely advises these and other health care industry clients on legislative and regulatory trends, including on issues such as drug pricing and risk adjustment.
Prior to joining Mintz, Xavier was an associate in the Washington, DC office of a national law firm. In that role, he advised clients on legal and regulatory issues around health care reimbursement involving Medicare, Medicaid, and other third-party payors. He also counseled clients on federal and state health care fraud and abuse laws, including the Stark Law and the anti-kickback statute.
While he was in law school, Xavier served as an intern in the US Department of Health and Human Services’ Office of Inspector General and Vermont Legal Aid’s Office of the Health Care Advocate. He also worked as a senior research assistant at The George Washington University Milliken Institute School of Public Health, where he contributed to projects around health care regulatory issues.
December 20, 2022 | Blog | By Lara Compton, Xavier Hardy
October 3, 2022 | Article | By Theresa Carnegie, Tara E. Dwyer, Xavier Hardy, Stephnie John, Bridgette Keller, Lauren Moldawer, Pat Ouellette, Hassan Shaikh
With Proposal to Cap Drug Price Increases, Massachusetts Once Again Takes Center Stage in the Drug Pricing Debate
April 22, 2022 | Blog | By Xavier Hardy
Health Law Diagnosed — Transactions Part 2: The Role of Health Regulatory Diligence and How to Prepare for a Sell-Side Transaction
March 24, 2022 | Podcast | By Tara E. Dwyer, Xavier Hardy, Bridgette Keller, Lauren Moldawer, Cassandra Paolillo, Kate Stewart
March 17, 2022 | Blog | By Xavier Hardy
March 3, 2022 | Podcast | By Susan Berson, Xavier Hardy, Bridgette Keller, Lauren Moldawer, Cassandra Paolillo, Kate Stewart
CMS Proposes Changes to Medicare Advantage Regulations: Network Adequacy, Beneficiary Access, MLR Reporting, and MOOP
January 19, 2022 | Blog | By Bridgette Keller, Xavier Hardy
July 27, 2020 | Blog | By Xavier Hardy, Daryl Berke
April 10, 2020 | Blog | By Xavier Hardy
News & Press
December 23, 2021
Monopsony Issues in the Post-ACA World: How the Affordable Care Act May Impact Monopsony Analyses in the Review of Health Insurance Mergers
October 1, 2016
Events & Speaking
- Member, American Health Lawyers Association